
Owlstone Medical Stock
Diagnostics company developing a breathalyzer for disease
Sign up today and learn more about Owlstone Medical Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Owlstone Medical Stock
Owlstone Medical’s vision is to save 100,000 lives by realizing the enormous promise of breath-based diagnostics through the development and application of Breath Biopsy®.
Owlstone Medical’s world-leading Breath Biopsy platform includes ReCIVA®, a proprietary sample collection device that can take stable breath samples anywhere, the world’s only commercial Breath Biopsy Laboratory located in Cambridge, U.K. with support through our office in Research Triangle Park, NC, USA, and the development of the world’s largest Digital Breath Biobank matched to patient phenotype.
Owlstone Medical is deploying the platform to address some of the key challenges of 21st century healthcare. The focus is on the development of Tests and RUO Panels for the early detection of disease with an emphasis on cancer, and on precision medicine initially targeting liver and respiratory disease.
The Breath Biopsy OMNI (Owlstone Medical Novel Insights) Assay is Owlstone Medical’s comprehensive solution for end-to-end breath sample collection and VOC analysis, which is being deployed with large pharma including AstraZeneca, Actelion Pharmaceuticals (a J&J company), and GlaxoSmithKline, and leading academic institutions. Owlstone Medical’s technology is currently in use at over 100 sites worldwide.
Investors
Aviva Ventures
Foxconn Technology Group
Horizons Ventures
Impossible Foods, Eat Just, Scopely, Improbable, Airwallex, Hippo Insurance, Divergent 3D, Blockstream, States Title, HZO
Medtekwiz Advisory Ltd
Ventura Capital
Funding History
March 2016 | $7.0M |
---|---|
December 2016 | $11.5M |
March 2018 | $15.0M |
January 2019 | $9.3M |
May 2019 | $10.4M |
September 2021 | $58.0M |
Management
Co-Founder & Chief Executive Officer
Billy Boyle
Co-Founder & Chief Operating Officer
David Ruiz Alonso
Chief Financial Officer
Martin Cartwright
Press
dlvr - Jun, 16 2023
Owlstone Medical delivers breath biopsy test datadlvr - Mar, 17 2023
Owlstone Medical collaborates with Bicycle Therapeuticsnews-medical - Dec, 10 2022
Owlstone Medical Presents Breath Biopsy® VOC Atlasbiospace - Jan, 24 2022
SQI Diagnostics Inc Signs MOU with UK-Based Owlstone Medicalfiercebiotech - Sep, 9 2021
Breath biopsy company Owlstone Medical hoovers up $58M funding roundbit - Sep, 9 2021
Owlstone Medical exceeds $50m target in financing roundbit - Sep, 8 2021
Global investors pile into $58m Owlstone Medical Series Dfinsmes - Sep, 7 2021
Owlstone Medical Raises $58M in Fundingbit - Jul, 21 2021
Owlstone Medical publishes findings of mask filter alternative to NPSbusinessweekly - Jun, 7 2021
PragmatIC blazes a Cambridge glory trial in top engineering awardbit - May, 19 2021
Owlstone breath biopsy to be used in gut researchbit - May, 18 2021
Collaboration aims to improves diagnosis of gut health problemsbit - Jan, 19 2021
Owlstone Medical introduces panel for respiratory disease researchbusinessweekly - Jan, 9 2021
Owlstone Medical hiring in UK and at expanded US basebit - Dec, 18 2020
Owlstone breath solution offers detection hope for range of diseasesfiercebiotech - Oct, 20 2020
Owlstone's breath-based biopsy test spots signs of declining liver functionhealthtechpulse - Jun, 10 2020
Owlstone Medical and Actelion to breathe new life into pulmonary hypertension diagnosisbit - May, 29 2020
Owlstone Medical appoints Tween as CFObusinessweekly - Apr, 5 2020
Owlstone Medical appoints Tween as CFObusinessweekly - Dec, 21 2019
Cambridge company brings disease breathalyser expertise to EU projectbusinessweekly - Nov, 14 2019
Cambridge biotech luminaries deliver masterclass on hiring and investmenthealthtechpulse - May, 21 2019
Owlstone Medical and Actelion to breathe new life into pulmonary hypertension diagnosismassdevice - May, 21 2019
Owlstone, Actelion ink collab pulmonary hypertension breath test dev dealbusinesswire - Feb, 21 2019
Owlstone Medical Partners with Shanghai Renji Hospital to Pioneer Breath Biopsy Lung Cancer Trial in Chinabusinesswire - Apr, 10 2018
Owlstone Medical Provides Breath Biopsy Services to AstraZeneca to Study Disease Drivers in Asthma and COPDmedcitynews - Apr, 10 2018
Owlstone Medical collaboration with AstraZeneca illustrates applications of breath biopsy kitbusinesswire - Mar, 29 2018
Owlstone Medical Launches Breath Biopsy Kitsnanalyze - Mar, 24 2018
9 Companies Pioneering Breath Diagnosticsfinsmes - Mar, 5 2018
Owlstone Medical Raises $15M in Fundingfiercebiotech - Mar, 5 2018
Owlstone raises $15M to bring cancer breath test to marketnews-medical - Jan, 27 2018
IPF Catalyst Challenge recognizes Owlstone Medical’s Breath Biopsy platformprnewswire - Jan, 26 2018
Three Lakes Partners Announces Winners of $1,000,000 IPF Catalyst Challengemassdevice - Mar, 5 2017
7 disruptive innovations from medical device suppliersEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase